Clinical Trial Update: ARID1A and/or KDM6A Mutation and CXCL13 Expression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update from MD Anderson investigating ARID1A and/or KDM6A mutation status and CXCL13 expression in urothelial cancers of the bladder, ren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Renal Pelvis Cancer
• Ureteral Cancer
• Urothelial Carcinoma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING